Aspirin-triggered resolvin D1 reduces parasitic cardiac load by decreasing inflammation in a murine model of early chronic Chagas disease
| Autor: | Ulrike Kemmerling, Christian Castillo, Daniela Guzmán-Rivera, César Barbosa, Helena Quintero, Guillermo Díaz-Araya, Fabiola González-Herrera, Fabiana S. Machado, Mariana Rates, Sebastián Fuentes-Retamal, Juan Diego Maya, Ileana Carrillo, Rayane Aparecida Nonato Rabelo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Chagas Cardiomyopathy
Male Physiology RC955-962 Cardiomyopathy Cancer Treatment Parasite load Parasite Load Mice Medical Conditions Fibrosis Arctic medicine. Tropical medicine Immune Physiology Medicine and Health Sciences Immune Response Protozoans Trypanosoma Cruzi Mice Knockout Innate Immune System biology Eukaryota Heart Animal Models Infectious Diseases Experimental Organism Systems Oncology Benznidazole Nitroimidazoles Cytokines Female medicine.symptom Public aspects of medicine RA1-1270 Anatomy medicine.drug Research Article Chagas disease Trypanosoma Docosahexaenoic Acids Inflammatory Diseases Immunology Inflammation Mouse Models Cytokine Therapy Research and Analysis Methods Signs and Symptoms Model Organisms medicine Parasitic Diseases Animals Humans Trypanosoma cruzi business.industry Myocardium Public Health Environmental and Occupational Health Organisms Biology and Life Sciences Molecular Development medicine.disease biology.organism_classification Receptors Formyl Peptide Parasitic Protozoans Mice Inbred C57BL Disease Models Animal Heart failure Immune System Chronic Disease Animal Studies Cardiovascular Anatomy Clinical Medicine business Developmental Biology |
| Zdroj: | PLoS Neglected Tropical Diseases PLoS Neglected Tropical Diseases, Vol 15, Iss 11, p e0009978 (2021) |
| ISSN: | 1935-2735 1935-2727 |
| Popis: | Background Chagas disease, caused by the protozoan Trypanosoma cruzi, is endemic in Latin America and is widely distributed worldwide because of migration. In 30% of cases, after years of infection and in the absence of treatment, the disease progresses from an acute asymptomatic phase to a chronic inflammatory cardiomyopathy, leading to heart failure and death. An inadequate balance in the inflammatory response is involved in the progression of chronic Chagas cardiomyopathy. Current therapeutic strategies cannot prevent or reverse the heart damage caused by the parasite. Aspirin-triggered resolvin D1 (AT-RvD1) is a pro-resolving mediator of inflammation that acts through N-formyl peptide receptor 2 (FPR2). AT-RvD1 participates in the modification of cytokine production, inhibition of leukocyte recruitment and efferocytosis, macrophage switching to a nonphlogistic phenotype, and the promotion of healing, thus restoring organ function. In the present study, AT-RvD1 is proposed as a potential therapeutic agent to regulate the pro-inflammatory state during the early chronic phase of Chagas disease. Methodology/Principal findings C57BL/6 wild-type and FPR2 knock-out mice chronically infected with T. cruzi were treated for 20 days with 5 μg/kg/day AT-RvD1, 30 mg/kg/day benznidazole, or the combination of 5 μg/kg/day AT-RvD1 and 5 mg/kg/day benznidazole. At the end of treatment, changes in immune response, cardiac tissue damage, and parasite load were evaluated. The administration of AT-RvD1 in the early chronic phase of T. cruzi infection regulated the inflammatory response both at the systemic level and in the cardiac tissue, and it reduced cellular infiltrates, cardiomyocyte hypertrophy, fibrosis, and the parasite load in the heart tissue. Conclusions/Significance AT-RvD1 was shown to be an attractive therapeutic due to its regulatory effect on the inflammatory response at the cardiac level and its ability to reduce the parasite load during early chronic T. cruzi infection, thereby preventing the chronic cardiac damage induced by the parasite. Author summary Chagas disease is prevalent in Latin America and is widely distributed worldwide due to migration. In 30% of patients, if the parasite is left untreated, the disease may progress from an acute symptomless phase to chronic myocardial inflammation, which can cause heart failure and death, years after the infection. Imbalances in the inflammatory response are related to this progression. Current treatments cannot prevent or reverse the cardiac damage inflicted by the parasite. Aspirin-triggered resolvin D1, also named AT-RvD1, can modify cellular and humoral inflammatory responses leading to the resolution of inflammation, thus promoting healing and restoring organ function. In this study, AT-RvD1, in an N-formyl peptide receptor 2 (FPR2)-dependent manner, was shown to regulate local and systemic inflammation and decrease cellular infiltration in the heart tissue of mice chronically infected with the parasite and reduce cardiac hypertrophy and fibrosis in the early stages of the chronic phase of the disease. Importantly, AT-RvD1 was able to decrease parasite load in the infected hearts. Thus, this research indicates that At-RvD1 treatment is a potential therapeutic strategy that offers an improvement on current drug therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|